InSite Vision Inc. (INSV)
Robertson, Stephens analyst Edward Hurwitz said the successful completion of INSV's Phase III trial of BetaSite formulation of levobunolol in glaucoma is a positive for the Alameda, Calif., company and he expects product approval in 1997 (see Clinical Results, page B6). But he added that he expects INSV to conduct additional studies to show the competitive advantage of the